It’s Time for an Actos Recall in the U.S., Says Attorney Michael J. Evans

“Big money and bad drugs are a dangerous combination,” says Attorney Michael J. Evans, owner of The Law Offices of Michael J. Evans, LLC,, says it’s time for an Actos recall in the United States. Evans posted the argument

in favor of an Actos recall on his website, Michael J. Evans, Law + Marketing + Technology,

Actos Recall Social Media Campaign

To try to build public support for an Actos recall, Evans has started a social media campaign to educate people about the risks of Actos and build support for an Actos Recall. The Actos social media campaign includes the following:

“France and Germany recalled Actos in June 2011 because studies showed the drug increased patients’ risks of bladder cancer and congestive heart failure. But in the U.S.,” Evans said, “the FDA merely issued a warning.

Evans says events of the past three months show that an Actos recall is needed now more than ever. Evans pointed to the following developments as proof that an Actos recall necessary:

[Continue reading…]

Actos lawsuit says actos bladder cancer link revealed by testing on rats.

Actos lawsuit filed by whistleblower alleges deliberate coverup of Actos side effects.

Actos lawsuit filed by whistleblower recently unsealed by federal court: A whistleblower who filed an actos lawsuit against the maker o

f Actos makes serious allegations about a coverup of the Actos bladder cancer link. (Download a copy of the 111-page Actos lawsuit here). The actos lawsuit was filed by whistleblower Helen Ge, who is a medical doctor and former safety consultant to Takeda Pharmaceuticals.

Dr. Helen Ge’s Actos lawsuit involves Takeda’s failure to report bladder cancer, Congestive Heart Failure (CHF) and other adverse events

for the diabetes drug Actos. In her lawsuit, Dr. Ge alleges shocking misconduct, including these allegations about the Actos bladder cancer risk:

Dr. Ge had direct knowledge of the Actos bladder cancer risk and encountered resistance from her superiors when she tried to report bladder cancer as related to Actos. Dr. Ge claims her supervisors directed her to change her “related” assessment to unrelated. According to her recollection of reviewing Takeda’s adverse event database for Actos, there were more than 100 bladder cancers reported to the company, but only 72 reported to the FDA, which she alleges is a serious discrepancy. Dr. Ge also alleges that carcinogenesis from Actos was discovered during the initial Actos animal studies.

Actos attorneys who have filed Actos lawsuits for people with bladder cancer are taking a long look at Dr.

Ge’s lawsuit. If the allegations of the lawsuit are true, Actos’ manufacturer could be facing substantial compensatory and punitive damages in each bladder cancer victim’s actos lawsuit. A jury would be understandably upset if these allegations are proven:

  • That Dr. Ge’s supervisors ordered her to falsely report that side effects related to Actos were “unrelated.”
  • That the link between Actos

    and bladder cancer was shown as early as animal studies, before Actos was ever placed on the market.

  • That there were more than 100 Actos bladder cancer cases, but Takeda Pharmaceuticals reported only 72 of them to the FDA.

(Download a copy of the 111-page Actos lawsuit here).